NEXGEL to Present at Maxim Group's 2022 Virtual Growth Conference
LANGHORNE, Pa., March 24, 2022 /PRNewswire/ -- NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participate in the Maxim Group 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022. Mr. Levy's corporate presentation will be available on-demand at the start of the conference. To attend, register here.
For more information on the Maxim conference, or to schedule a meeting with NEXGEL's management team, please reach out to a Maxim representative or contact KCSA Strategic Communications at [email protected].
About NEXGEL, INC.NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contacts:Valter Pinto / Nick StaabKCSA Strategic Communications212.896.1254 / 212.896.1254[email protected] / [email protected]
Media Contacts:Raquel ConaKCSA Strategic Communications212.896.1204[email protected]
View original content:https://www.prnewswire.com/news-releases/nexgel-to-present-at-maxim-groups-2022-virtual-growth-conference-301509663.html
SOURCE NEXGEL
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stop Letting Rogue Server Hosts Steal Your Client Data: Morpheus and Secret Network Unveil Unhackable, Zero-Snoop AI Infrastructure
- NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
- Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Live
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share